Literature DB >> 7766740

A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.

M Robinson1, B Sahba, D Avner, N Jhala, P A Greski-Rose, D E Jennings.   

Abstract

BACKGROUND: Lansoprazole is a new proton pump inhibitor which produces prolonged decrease of gastric acidity. The aim of this study was to compare lansoprazole to a standard dose of ranitidine in the treatment of patients with reflux oesophagitis.
METHODS: Two hundred and forty-seven patients with erosive oesophagitis were randomly assigned to 8 weeks of treatment with either 30 mg lansoprazole once daily or 150 mg ranitidine twice daily.
RESULTS: Two hundred and forty-two patients were included in the analysis. Lansoprazole (30 mg) daily, healed oesophagitis in 92.1% of patients after 8 weeks of treatment. This was significantly superior to 150 mg ranitidine b.d.s. which healed oesophagitis in 69.9% of patients (P < 0.001). Relief of reflux symptoms was superior with lansoprazole to that with ranitidine. Both lansoprazole and ranitidine were well tolerated with no serious drug-related adverse events noted.
CONCLUSION: Lansoprazole, 30 mg once daily, is highly effective and safe in the short-term treatment of erosive oesophagitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7766740     DOI: 10.1111/j.1365-2036.1995.tb00347.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  26 in total

Review 1.  Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.

Authors:  Wei-Hong Wang; Jia-Qing Huang; Ge-Fan Zheng; Harry Hua-Xiang Xia; Wai-Man Wong; Shiu-Kum Lam; Benjamin Chun-Yu Wong
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

3.  The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders.

Authors:  Muhammad Ali Khan; Colin W Howden
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

Review 4.  Safety profile of Lansoprazole: the US clinical trial experience.

Authors:  J W Freston; P A Rose; C A Heller; M Haber; D Jennings
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

5.  Long-term comparison of antireflux surgery versus conservative therapy for reflux esophagitis.

Authors:  J Isolauri; M Luostarinen; M Viljakka; E Isolauri; O Keyriläinen; A L Karvonen
Journal:  Ann Surg       Date:  1997-03       Impact factor: 12.969

Review 6.  A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.

Authors:  N Sharma; C Donnellan; C Preston; B Delaney; G Duckett; P Moayyedi
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

7.  Medical or surgical therapy for erosive reflux esophagitis: cost-utility analysis using a Markov model.

Authors:  Joseph Romagnuolo; Michael A Meier; Daniel C Sadowski
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

8.  Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis.

Authors:  Colin W Howden; E David Ballard; Weining Robieson
Journal:  Clin Drug Investig       Date:  2002       Impact factor: 2.859

9.  Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration.

Authors:  R J Brummer; B J Geerling; R W Stockbrügger
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

Review 10.  Trends in the management of gastro-oesophageal reflux disease.

Authors:  J M Lee; C A O'Morain
Journal:  Postgrad Med J       Date:  1998-03       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.